Brokerages Set Blueprint Medicines Co. (NASDAQ:BPMC) PT at $85.43

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have earned an average rating of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $85.43.

A number of equities research analysts have recently issued reports on BPMC shares. JMP Securities reaffirmed a “market outperform” rating and set a $114.00 target price on shares of Blueprint Medicines in a research report on Friday, February 16th. Barclays boosted their target price on Blueprint Medicines from $58.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 13th. Citigroup boosted their target price on Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a research report on Friday, February 16th. Stifel Nicolaus lifted their price target on Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a report on Monday, February 26th.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, CFO Michael Landsittel sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $95.00, for a total value of $475,000.00. Following the completion of the transaction, the chief financial officer now owns 47,286 shares of the company’s stock, valued at approximately $4,492,170. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Michael Landsittel sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $95.00, for a total value of $475,000.00. Following the sale, the chief financial officer now directly owns 47,286 shares in the company, valued at approximately $4,492,170. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey W. Albers sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $81.91, for a total value of $2,047,750.00. Following the completion of the sale, the director now owns 176,050 shares in the company, valued at $14,420,255.50. The disclosure for this sale can be found here. Insiders sold a total of 117,289 shares of company stock valued at $10,361,913 in the last quarter. Corporate insiders own 3.88% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. grew its holdings in Blueprint Medicines by 5.2% during the 3rd quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock worth $33,696,000 after acquiring an additional 33,243 shares during the last quarter. Diversified Trust Co raised its holdings in shares of Blueprint Medicines by 2.9% in the third quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock valued at $563,000 after purchasing an additional 318 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Blueprint Medicines by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 757 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in shares of Blueprint Medicines by 17.4% in the third quarter. Rafferty Asset Management LLC now owns 166,690 shares of the biotechnology company’s stock valued at $8,371,000 after purchasing an additional 24,693 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Blueprint Medicines by 0.6% in the third quarter. Vanguard Group Inc. now owns 5,967,143 shares of the biotechnology company’s stock valued at $299,670,000 after purchasing an additional 37,716 shares during the last quarter.

Blueprint Medicines Stock Up 1.1 %

BPMC opened at $91.65 on Friday. Blueprint Medicines has a one year low of $41.75 and a one year high of $101.00. The company has a debt-to-equity ratio of 1.60, a quick ratio of 3.66 and a current ratio of 3.76. The stock’s fifty day moving average is $87.66 and its 200-day moving average is $74.94. The company has a market capitalization of $5.61 billion, a PE ratio of -10.96 and a beta of 0.63.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The company had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. During the same quarter in the previous year, the business earned ($2.65) EPS. The company’s quarterly revenue was up 85.5% compared to the same quarter last year. On average, equities analysts predict that Blueprint Medicines will post -5.42 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.